Dampening of the respiratory cytokine storm is promoted by inhaled budesonide in patients with early COVID-19

Baker et al., medRxiv, doi:10.1101/2021.10.26.21265512, Oct 2021

Budesonide for COVID-19

27th treatment shown to reduce risk in September 2021, now with p = 0.000003 from 15 studies, recognized in 10 countries.

No treatment is 100% effective.
Protocols combine treatments.

Analysis of inflammatory mediators in the nasal mucosa of patients in the STOIC1 trial and a cohort of SARS-CoV-2 negative controls, showing that budesonide treatment decreased IL-33 and IFN-γ, implying a reduction in epithelial damage and dampening of the interferon response. Treatment also increased CCL17 concentrations, suggesting improved T-cell response.
Baker et al., 27 Oct 2021, preprint, 10 authors.
Dampening of the respiratory cytokine storm is promoted by inhaled budesonide in patients with early COVID-19
Jonathan R Baker, Mahdi Mahdi, Dan V Nicolau Jr, Sanjay Ramakrishnan, Peter J Barnes, Jodie L Simpson, Steven P Cass, Richard Ek Russell, Louise E Donnelly, Professor Mona Bafadhel
doi:10.1101/2021.10.26.21265512
Vaccinations against SARS-CoV-2 are effective in COVID-19. However, with limited vaccine access, vaccine hesitancy and variant breakthroughs, there is still a need for effective and safe early treatments. Two community-based clinical trials of the inhaled corticosteroid, budesonide, have recently been published showing and improvement in patients with COVID-19 treated early with budesonide 1,2 . To understand mechanistically how budesonide was beneficial, inflammatory mediators were assessed in the nasal mucosa of patients recruited to the Steroids in COVID (STOIC 1 ) trial and a cohort of SARS-CoV-2 negative individuals. Here we show that in early COVID-19, elevation in viral response proteins and Th1 and Th2 inflammation occurs. Longitudinal sampling in the natural course of COVID-19 showed persistently high interferon levels and elevated concentrations of the eosinophil chemokine, CCL11. In patients who deteriorate, the initial nasal mucosal signal is characterised by a marked suppression of the early inflammatory response, with reduced concentrations of interferon and inflammatory cytokines, but elevated eosinophil chemokines. Systemic inflammation remained altered in COVID-19 patients, implying that even after symptom resolution, changes in immunological mediators do not resolve. Budesonide treatment decreased IL-33 and IFN-γ, implying a reduction in epithelial damage and dampening of the interferon response. Budesonide treatment also increased CCL17 concentrations, suggesting an improved T-cell response; and significantly alters inflammatory pathways giving further insight into how this treatment can accelerate patient recovery. . This finding has now been replicated in a large Phase 3 efficacy trial 2 , but has yet to attract global adoption. The mechanism for how ICS can improve early COVID-19 infection is however currently unknown. Here, we report the nasal mucosal inflammatory response in patients with early COVID-19 disease and examine the evolution of inflammation in the natural course of COVID-19. We also identify how inflammation in the airway can predict illness severity and investigate the effect of inhaled budesonide upon the respiratory mucosa in early COVID-19 disease. Finally, we show using network analysis how inhaled budesonide can resolve the exaggerated inflammatory response seen in early COVID-19 infection and promote resolution to health.
Methods Study design and participants STOIC was a randomised, open-label, parallel group, phase 2 clinical intervention trial. Participants aged 18 and over with early COVID-19 symptoms (defined as new onset of cough and/or fever and/or anosmia for less than 7 days) were randomised to receive usual care (UC), namely as required anti-pyretics, or inhaled budesonide (BUD) at a dose of 800μg twice a day plus usual care (see supplement figure S1 ). Participants were seen at home at randomisation day 0 (visit 1), day 7 (visit 2), and day 14 (visit 3) by a research nurse to obtain consent, provide inhalers and collect nasal absorption samples and nasopharyngeal swabs which were self-performed. At day 28 (visit 4), whole Nasal mucosal sampling Nasal mucosal sampling was self-performed by all participants as previously described 37 . Briefly, samples of the nasal mucosal lining fluid were collected by placing a Nasosorption™ FX•I device (Hunt Developments UK Ltd) consisting of a synthetic absorptive matrix strip against the inferior turbinate for a duration of 1 minute. The sample was then eluted in 500 μL of PBS, 1% bovine serum albumin (BSA) (w/v), 1% Triton X-100 (v/v), and 0.05% sodium azide (w/v) (Sigma-Aldrich, UK) and stored at -80°C. Isolation of serum
References
Bafadhel, Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers, Am J Respir Crit Care Med, doi:10.1164/rccm.201104-0597OC
Bafadhel, Pavord, Russell, Eosinophils in COPD: just another biomarker?, Lancet Respir Med, doi:10.1016/S2213-2600(17)30217-5
Barnes, Inhaled Corticosteroids, Pharmaceuticals, doi:10.3390/ph3030514
Blondel, Guillaume, Lambiotte, Lefebvre, Fast unfolding of communities in large networks, Journal of Statistical Mechanics: Theory and Experiment, doi:10.1088/1742-5468/2008/10/p10008
Bloom, Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK, Lancet Respir Med, doi:10.1016/S2213-2600(21)00013-8
Chua, COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis, Nature Biotechnology, doi:10.1038/s41587-020-0602-4
Farr, Altered microRNA expression in COVID-19 patients enables identification of SARS-CoV-2 infection, PLoS Pathog, doi:10.1371/journal.ppat.1009759
Finney, Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon, The Journal of allergy and clinical immunology, doi:10.1016/j.jaci.2020.09.034
Gleich, Mechanisms of eosinophil-associated inflammation, J Allergy Clin Immunol, doi:10.1067/mai.2000.105712
Guan, Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis, Eur Respir J, doi:10.1183/13993003.00547-2020
Guo-Parke, Linden, Weldon, Kidney, Taggart, Mechanisms of Virus-Induced Airway Immunity Dysfunction in the Pathogenesis of COPD Disease, Progression, and Exacerbation, Frontiers in Immunology, doi:10.3389/fimmu.2020.01205
Hadjadj, Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients, Science, doi:10.1126/science.abc6027
Han, Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors, Emerging Microbes & Infections, doi:10.1080/22221751.2020.1770129
Hoffmann, SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell, doi:10.1016/j.cell.2020.02.052
Iyengar, Jain, Vaishya, Ish, Long COVID-19: an emerging pandemic in itself, Adv Respir Med, doi:10.5603/ARM.a2021.0040
Lee, Ashkar, The Dual Nature of Type I and Type II Interferons, Frontiers in Immunology, doi:10.3389/fimmu.2018.02061
Leist, Schäfer, Martinez, Cell and animal models of SARS-CoV-2 pathogenesis and immunity, Disease Models & Mechanisms, doi:10.1242/dmm.046581
Liao, Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19, Nature Medicine, doi:10.1038/s41591-020-0901-9
Lucas, Longitudinal analyses reveal immunological misfiring in severe COVID-19, Nature, doi:10.1038/s41586-020-2588-y
Marchenko, Pastur, Распределение собственных значений в некоторых ансамблях случайных матриц
Mason, Thoughts on the alveolar phase of COVID-19, American Journal of Physiology-Lung Cellular and Molecular Physiology, doi:10.1152/ajplung.00126.2020
Message, Johnston, The immunology of virus infection in asthma, European Respiratory Journal, doi:10.1183/09031936.01.00228701
Milne, Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a randomised controlled trial, Eur Respir J, doi:10.1183/13993003.00130-2021
Morton, Distinct clinical and immunological profiles of patients with evidence of SARS-CoV-2 infection in sub-Saharan Africa, Nature communications, doi:10.1038/s41467-021-23267-w
Murira, Lamarre, Type-I Interferon Responses: From Friend to Foe in the Battle against Chronic Viral Infection, Frontiers in Immunology, doi:10.3389/fimmu.2016.00609
Papi, Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations, Am J Respir Crit Care Med, doi:10.1164/rccm.200506-859OC
Peluso, Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms, Cell Rep, doi:10.1016/j.celrep.2021.109518
Ramakrishnan, Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial, Lancet Respir Med, doi:10.1016/s2213-2600(21)00160-0
Rogliani, Lauro, Di Daniele, Chetta, Calzetta, Reduced risk of COVID-19 hospitalization in asthmatic and COPD patients: a benefit of inhaled corticosteroids?, Expert Rev Respir Med, doi:10.1080/17476348.2021.1850275
Rouse, Sehrawat, Immunity and immunopathology to viruses: what decides the outcome?, Nature Reviews Immunology, doi:10.1038/nri2802
Saris, Distinct cellular immune profiles in the airways and blood of critically ill patients with COVID-19, Thorax, doi:10.1136/thoraxjnl-2020-216256
Scheller, Chalaris, Garbers, Rose-John, ADAM17: a molecular switch to control inflammation and tissue regeneration, Trends in Immunology, doi:10.1016/j.it.2011.05.005
Sudre, Attributes and predictors of long COVID, Nature Medicine, doi:10.1038/s41591-021-01292-y
Tan, Viruses in asthma exacerbations, Curr Opin Pulm Med, doi:10.1097/01.mcp.0000146781.11092.0d
Thwaites, Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19, Sci Immunol, doi:10.1126/sciimmunol.abg9873
Valle, An inflammatory cytokine signature predicts COVID-19 severity and survival, Nature medicine, doi:10.1038/s41591-020-1051-9
Vareille, Kieninger, Edwards, Regamey, The airway epithelium: soldier in the fight against respiratory viruses, Clin Microbiol Rev, doi:10.1128/CMR.00014-10
Yamaya, Nishimura, Nadine, Kubo, Nagatomi, Formoterol and budesonide inhibit rhinovirus infection and cytokine production in primary cultures of human tracheal epithelial cells, Respir Investig, doi:10.1016/j.resinv.2014.03.004
Yu, Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial, Lancet, doi:10.1016/S0140-6736(21)01744-X
Zhou, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3
DOI record: { "DOI": "10.1101/2021.10.26.21265512", "URL": "http://dx.doi.org/10.1101/2021.10.26.21265512", "abstract": "<jats:title>Summary</jats:title><jats:p>Vaccinations against SARS-CoV-2 are effective in COVID-19. However, with limited vaccine access, vaccine hesitancy and variant breakthroughs, there is still a need for effective and safe early treatments. Two community-based clinical trials of the inhaled corticosteroid, budesonide, have recently been published showing and improvement in patients with COVID-19 treated early with budesonide<jats:sup>1,2</jats:sup>. To understand mechanistically how budesonide was beneficial, inflammatory mediators were assessed in the nasal mucosa of patients recruited to the Steroids in COVID (STOIC<jats:sup>1</jats:sup>) trial and a cohort of SARS-CoV-2 negative individuals. Here we show that in early COVID-19, elevation in viral response proteins and Th1 and Th2 inflammation occurs. Longitudinal sampling in the natural course of COVID-19 showed persistently high interferon levels and elevated concentrations of the eosinophil chemokine, CCL11. In patients who deteriorate, the initial nasal mucosal signal is characterised by a marked suppression of the early inflammatory response, with reduced concentrations of interferon and inflammatory cytokines, but elevated eosinophil chemokines. Systemic inflammation remained altered in COVID-19 patients, implying that even after symptom resolution, changes in immunological mediators do not resolve. Budesonide treatment decreased IL-33 and IFN-γ, implying a reduction in epithelial damage and dampening of the interferon response. Budesonide treatment also increased CCL17 concentrations, suggesting an improved T-cell response; and significantly alters inflammatory pathways giving further insight into how this treatment can accelerate patient recovery.</jats:p><jats:sec><jats:title>Abstract Figure</jats:title><jats:fig id=\"ufig1\" position=\"float\" fig-type=\"figure\" orientation=\"portrait\"><jats:graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"21265512v1_ufig1\" position=\"float\" orientation=\"portrait\" /></jats:fig></jats:sec>", "accepted": { "date-parts": [ [ 2021, 10, 27 ] ] }, "author": [ { "affiliation": [], "family": "Baker", "given": "Jonathan R", "sequence": "first" }, { "affiliation": [], "family": "Mahdi", "given": "Mahdi", "sequence": "additional" }, { "affiliation": [], "family": "Nicolau", "given": "Dan V", "sequence": "additional", "suffix": "Jr." }, { "ORCID": "http://orcid.org/0000-0002-3003-7918", "affiliation": [], "authenticated-orcid": false, "family": "Ramakrishnan", "given": "Sanjay", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-5122-4018", "affiliation": [], "authenticated-orcid": false, "family": "Barnes", "given": "Peter J", "sequence": "additional" }, { "affiliation": [], "family": "Simpson", "given": "Jodie L", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-7032-6239", "affiliation": [], "authenticated-orcid": false, "family": "Cass", "given": "Steven P", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-3890-7201", "affiliation": [], "authenticated-orcid": false, "family": "Russell", "given": "Richard EK", "sequence": "additional" }, { "affiliation": [], "family": "Donnelly", "given": "Louise E", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-9993-2478", "affiliation": [], "authenticated-orcid": false, "family": "Bafadhel", "given": "Mona", "sequence": "additional" } ], "container-title": [], "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2021, 10, 29 ] ], "date-time": "2021-10-29T14:55:17Z", "timestamp": 1635519317000 }, "deposited": { "date-parts": [ [ 2021, 10, 29 ] ], "date-time": "2021-10-29T14:55:21Z", "timestamp": 1635519321000 }, "group-title": "Infectious Diseases (except HIV/AIDS)", "indexed": { "date-parts": [ [ 2022, 3, 31 ] ], "date-time": "2022-03-31T12:47:50Z", "timestamp": 1648730870091 }, "institution": [ { "name": "medRxiv" } ], "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2021, 10, 27 ] ] }, "link": [ { "URL": "https://syndication.highwire.org/content/doi/10.1101/2021.10.26.21265512", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "246", "original-title": [], "posted": { "date-parts": [ [ 2021, 10, 27 ] ] }, "prefix": "10.1101", "published": { "date-parts": [ [ 2021, 10, 27 ] ] }, "publisher": "Cold Spring Harbor Laboratory", "reference": [ { "DOI": "10.1016/s22132600(21)00160-0", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.1" }, { "DOI": "10.1016/S0140-6736(21)01744-X", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.2" }, { "DOI": "10.1242/dmm.046581", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.3" }, { "DOI": "10.1016/j.celrep.2021.109518", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.4" }, { "DOI": "10.1371/journal.ppat.1009759", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.5" }, { "DOI": "10.1038/nri2802", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.6" }, { "DOI": "10.1183/09031936.01.00228701", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.7" }, { "DOI": "10.3389/fimmu.2020.01205", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.8" }, { "DOI": "10.1097/01.mcp.0000146781.11092.0d", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.9" }, { "DOI": "10.1164/rccm.200506-859OC", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.10" }, { "DOI": "10.1164/rccm.201104-0597OC", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.11" }, { "DOI": "10.1183/13993003.00547-2020", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.12" }, { "DOI": "10.1080/17476348.2021.1850275", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.13" }, { "DOI": "10.1016/S2213-2600(21)00013-8", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.14" }, { "DOI": "10.1038/s41467-021-23267-w", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.15" }, { "DOI": "10.1038/s41586-020-2588-y", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.16" }, { "DOI": "10.1038/s41591-020-0901-9", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.17" }, { "DOI": "10.1038/s41587-020-0602-4", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.18" }, { "DOI": "10.1080/22221751.2020.1770129", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.19" }, { "DOI": "10.1152/ajplung.00126.2020", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.20" }, { "DOI": "10.1128/CMR.00014-10", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.21" }, { "DOI": "10.1126/science.abc6027", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.22" }, { "DOI": "10.1067/mai.2000.105712", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.23" }, { "DOI": "10.1016/S0140-6736(20)30566-3", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.24" }, { "DOI": "10.1016/S2213-2600(17)30217-5", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.25" }, { "DOI": "10.5603/ARM.a2021.0040", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.26" }, { "DOI": "10.1136/thoraxjnl-2020-216256", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.27" }, { "DOI": "10.1038/s41591-021-01292-y", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.28" }, { "DOI": "10.3389/fimmu.2018.02061", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.29" }, { "DOI": "10.3389/fimmu.2016.00609", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.30" }, { "DOI": "10.1016/j.cell.2020.02.052", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.31" }, { "DOI": "10.1016/j.jaci.2020.09.034", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.32" }, { "DOI": "10.1183/13993003.001302021", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.33" }, { "DOI": "10.1016/j.resinv.2014.03.004", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.34" }, { "DOI": "10.3390/ph3030514", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.35" }, { "DOI": "10.1016/j.it.2011.05.005", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.36" }, { "DOI": "10.3791/56413", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.37" }, { "DOI": "10.1126/sciimmunol.abg9873", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.38" }, { "DOI": "10.1038/s41591-020-1051-9", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.39" }, { "article-title": "Распределение собственных значений в некоторых ансамблях случайных матриц” [Distribution of eigenvalues for some sets of random matrices]", "first-page": "507", "journal-title": "Mat. Sb", "key": "2021102907550968000_2021.10.26.21265512v1.40", "volume": "72", "year": "1967" }, { "DOI": "10.1088/1742-5468/2008/10/p10008", "doi-asserted-by": "publisher", "key": "2021102907550968000_2021.10.26.21265512v1.41" } ], "reference-count": 41, "references-count": 41, "relation": {}, "resource": { "primary": { "URL": "http://medrxiv.org/lookup/doi/10.1101/2021.10.26.21265512" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "subtype": "preprint", "title": "Dampening of the respiratory cytokine storm is promoted by inhaled budesonide in patients with early COVID-19", "type": "posted-content" }